Westlake Village-based dermatology biotech Sienna Biopharmaceuticals announced Sept. 17 that it will file Chapter 11 bankruptcy to restructure the company. Shares plunged 65 percent on the news, falling to just 24 cents as of 10 a.m., for a market capitalization of $7.4 million. The company had previously announced that it was considering a range of…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
